HUDSON, N.Y., April 26, 2017 -- Taconic Biosciences, a global leader in genetically engineered mouse models and associated services and the only commercial provider of germ-free mice, announced that effective April 26, 2017 they will expand their microbiome product and services platform to include custom Fecal Microbiota Transplantation (FMT) services. To support these new FMT services, Taconic will also offer custom germ-free derivations using either client mouse models, Taconic’s commercial offerings, or mice sourced from third parties.
This new FMT service offering capitalizes on Taconic’s decades of microbiome experience, existing portfolio of germ-free offerings including Germ-Free C57BL/6NTac and Swiss Webster mice, and ability to derive germ-free animals from Taconic’s large catalog of mutant mice or client-provided models.
Dr. Alexander Maue, Taconic Biosciences’ portfolio director for microbiome products and services, commented, “The germ-free mouse is the ideal substrate to evaluate the properties of complex or defined gut microbiota following FMT. Axenic mice transplanted with donor microbiota can be used to assess the effects of gut bacteria on a wide range of biological systems, including but not limited to, immunity, neurodegenerative diseases, obesity, and diabetes.”
“Our custom germ-free derivation services enable Taconic to generate initial cohorts of up to 40 germ-free animals, allowing researchers to generate rapid study cohorts.”
Prior to the start of any custom FMT project or germ-free derivation service, Taconic consults with the client to understand their research goals and develop a strategy for project execution. A dedicated Project Manager will keep clients updated throughout the project. Following FMT, Taconic offers a range of husbandry options to accommodate studies of all sizes and durations including options for isolators and state of the art individually ventilated cages (IVCs).
In addition to providing microbiome products and services, Taconic also is a fully-licensed provider of rodent model generation services and has twenty years of model design experience. Complimenting this expertise is Taconic’s unique capability of providing a seamless transition from model design to breeding and colony management, thus offering customers a complete solution. These scientific services include acquiring or generating, importing, licensing, breeding, testing, preparing, and distributing genetically engineered models to any location worldwide.
To learn more about Taconic’s microbiome products and services, please contact Taconic Biosciences at 1-888-TACONIC (888-822-6642) in the US, +45 70 23 04 05 in Europe or at [email protected].
About Taconic Biosciences, Inc.
Taconic Biosciences is a fully-licensed, global leader in genetically engineered rodent models and services. Founded in 1952, Taconic helps biotechnology companies and institutions acquire, custom generate, breed, precondition, test, and distribute valuable research models worldwide. Specialists in genetically engineered mouse and rat models, precision research mouse models, and integrated model design and breeding services, Taconic operates three service laboratories and six breeding facilities in the U.S. and Europe, maintains distributor relationships in Asia and has global shipping capabilities to provide animal models almost anywhere in the world.
Media Contact: Kelly Owen Grover Director of Marketing Communications (518) 697-3824 [email protected]


Nvidia CEO Jensen Huang Says AI Investment Boom Is Just Beginning as NVDA Shares Surge
Washington Post Publisher Will Lewis Steps Down After Layoffs
Sony Q3 Profit Jumps on Gaming and Image Sensors, Full-Year Outlook Raised
CK Hutchison Launches Arbitration After Panama Court Revokes Canal Port Licences
SpaceX Pushes for Early Stock Index Inclusion Ahead of Potential Record-Breaking IPO
Missouri Judge Dismisses Lawsuit Challenging Starbucks’ Diversity and Inclusion Policies
Once Upon a Farm Raises Nearly $198 Million in IPO, Valued at Over $724 Million
OpenAI Expands Enterprise AI Strategy With Major Hiring Push Ahead of New Business Offering
Hims & Hers Halts Compounded Semaglutide Pill After FDA Warning
TrumpRx Website Launches to Offer Discounted Prescription Drugs for Cash-Paying Americans
Alphabet’s Massive AI Spending Surge Signals Confidence in Google’s Growth Engine
American Airlines CEO to Meet Pilots Union Amid Storm Response and Financial Concerns
Nvidia, ByteDance, and the U.S.-China AI Chip Standoff Over H200 Exports
Uber Ordered to Pay $8.5 Million in Bellwether Sexual Assault Lawsuit
Baidu Approves $5 Billion Share Buyback and Plans First-Ever Dividend in 2026
Amazon Stock Rebounds After Earnings as $200B Capex Plan Sparks AI Spending Debate
SpaceX Prioritizes Moon Mission Before Mars as Starship Development Accelerates 



